- Home
- VSTS vs ATXS Comparison
VSTS vs ATXS Comparison
Compare VSTS & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTS
- ATXS
- Stock Information
- Founded
- VSTS 1936
- ATXS 2008
- Country
- VSTS United States
- ATXS United States
- Employees
- VSTS N/A
- ATXS N/A
- Industry
- VSTS
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- VSTS
- ATXS Health Care
- Exchange
- VSTS Nasdaq
- ATXS Nasdaq
- Market Cap
- VSTS 572.2M
- ATXS 676.1M
- IPO Year
- VSTS N/A
- ATXS 2015
- Fundamental
- Price
- VSTS $5.30
- ATXS $12.49
- Analyst Decision
- VSTS Sell
- ATXS Buy
- Analyst Count
- VSTS 4
- ATXS 7
- Target Price
- VSTS $9.13
- ATXS $30.00
- AVG Volume (30 Days)
- VSTS 2.0M
- ATXS 4.3M
- Earning Date
- VSTS 11-21-2025
- ATXS 11-12-2025
- Dividend Yield
- VSTS 1.34%
- ATXS N/A
- EPS Growth
- VSTS N/A
- ATXS N/A
- EPS
- VSTS N/A
- ATXS N/A
- Revenue
- VSTS $2,707,109,000.00
- ATXS N/A
- Revenue This Year
- VSTS N/A
- ATXS N/A
- Revenue Next Year
- VSTS $0.29
- ATXS N/A
- P/E Ratio
- VSTS N/A
- ATXS N/A
- Revenue Growth
- VSTS N/A
- ATXS N/A
- 52 Week Low
- VSTS $3.98
- ATXS $3.56
- 52 Week High
- VSTS $17.83
- ATXS $12.72
- Technical
- Relative Strength Index (RSI)
- VSTS 59.39
- ATXS 72.25
- Support Level
- VSTS $4.83
- ATXS $12.12
- Resistance Level
- VSTS $5.35
- ATXS $12.65
- Average True Range (ATR)
- VSTS 0.22
- ATXS 0.22
- MACD
- VSTS -0.00
- ATXS -0.15
- Stochastic Oscillator
- VSTS 82.61
- ATXS 64.34
About VSTS Vestis Corporation
Vestis Corp is a provider of uniform rentals and workplace supplies across the United States and Canada. It provides uniforms, mats, towels, linens, restroom supplies, first-aid supplies, safety products, and other workplace supplies. The Company serves customers ranging from small, family-owned operations with a single location to large corporations and national franchises with multiple locations. The company operates in the United States and Canada as reportable segments. The company earns the majority of its revenue from the United States.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.